NCT06145282View on ClinicalTrials.gov

Non-myeloablative Haploidentical HCT Study for Patients With Sickle Cell Disease, Including Compromised Organ Function

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

December 28, 2023

Primary Completion Date

November 26, 2025

Study Completion Date

November 26, 2027

Conditions
Sickle Cell Disease
Interventions
DRUG

Non-myeloablative haploidentical peripheral blood stem cell transplantation with briquilimab and abatacept

All participants will receive the same dose of the investigational briquilimab antibody and abatacept added to the NIH-established regimen of alemtuzumab-TBI-sirolimus and infusion of filgrastim-mobilized peripheral blood hematopoietic cells from haploidentical related donors.

Trial Locations (1)

20892

National Institutes of Health Clinical Center, Bethesda

All Listed Sponsors
lead

National Heart, Lung, and Blood Institute (NHLBI)

NIH

NCT06145282 - Non-myeloablative Haploidentical HCT Study for Patients With Sickle Cell Disease, Including Compromised Organ Function | Biotech Hunter | Biotech Hunter